BANK VONTOBEL/PUT/BIOGEN IDEC/260/0.01/21.06.24 | Market Closed - Deutsche Boerse AG 01:42:17 2024-06-14 pm EDT | ||
| 0.24 EUR | -4.00% |
|
| Current month | -24.24% | ||
| 1 month | -24.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.24 | -4.00% |
| 24-06-13 | 0.25 | -10.71% |
| 24-06-12 | 0.28 | -9.68% |
| 24-06-11 | 0.31 | +3.33% |
| 24-06-10 | 0.3 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU9CS1 |
| ISIN | DE000VU9CS14 |
| Date issued | 2023-07-03 |
| Strike | 260 $ |
| Maturity | 2024-06-21 (7 Days) |
| Parity | 100 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.66 € |
|---|---|
| Lowest since issue | 0.168 € |
| Spread | 0.05 € |
| Spread % | 17.86% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
233.8
USD
Average target price
284.6
USD
Spread / Average Target
+21.73%
- Stock Market
- Warrants
- Warrant
